Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Isoquercetin; Q Force; QB3C; QU995; Quercetin-3-O-glucoside

Latest Information Update: 22 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Chemical Reagent Factory; Catholic University of the Sacred Heart - Rome; Farr Laboratories LLC; Indiana University School of Medicine; Quercegen Pharmaceuticals; Singapore General Hospital; SRI International; Taiyuan Pharmaceutical Factory; University of Birmingham; University of California at Los Angeles; University of Ulster
  • Developer Dana-Farber Cancer Institute; National Institutes of Health (USA); Quercegen Pharmaceuticals; University of Michigan
  • Class Flavonoids; Small molecules
  • Mechanism of Action Antioxidants; Enzyme inhibitors; Free radical scavengers; Platelet aggregation inhibitors; Prostaglandin synthase stimulants; Protein tyrosine kinase inhibitors; Thromboxane A2 synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Thromboembolism
  • Phase I/II Chronic obstructive pulmonary disease
  • Discontinued Atherosclerosis; Cancer; Cardiovascular disorders; Prostatitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 Jan 2018 Quercetin is still in phase II/III trials for Thromboembolism (Prevention) in USA (PO) (NCT02195232)
  • 08 Dec 2016 M. D. Anderson Cancer Center plans a phase 0 trial for Chemotherapy induced neuropathic pain in USA (NCT02989129)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top